Whether adjuvant radiotherapy is desired for postmastectomy patients with T1–T2 tumors and 1–3 positive axillary lymph nodes who received modern systemic therapy?

The role of postmastectomy radiation therapy (PMRT) for patients with T1–T2 tumors and 1–3 positive axillary lymph node (ALN) metastases of breast cancer is an issue of ongoing debate. The uncertainty and controversy concerning PMRT for this group of patients is mainly due to the discrepancy in the conflicting benefits of locoregional control reported in different trials and in adjuvant systemic treatment eras (1-4)